Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Discovers Possible Lung Cancer Biomarker

NEW YORK (GenomeWeb News) – Compugen today stated that it has discovered and tested a potential blood-based small cell lung cancer biomarker that is it has named CGEN-438.
The proposed biomarker is a splice variant of the delta-like protein 3 precursor, DLL3. Previous observations suggest that DLL3 mutations and over-expression are associated with cancer. But CGEN-438 shares no sequence similarity to the membrane protein DLL3. And, unlike DLL3, CGEN-438 is reportedly secreted into the bloodstream.
CGEN-438 is one of a group of possible cancer and cardiovascular biomarkers predicted by Compugen’s immunoassay computational discovery platform. The company has developed a test to detect CGEN-438 and has filed a patent application covering the prospective biomarker.
To test the validity of CGEN-438 as a biomarker, Compugen scientists measured the serum levels of CGEN-438 in 40 lung cancer patients and healthy controls. They reportedly found that serum CGEN-438 levels were higher in small cell lung cancer patients than in control individuals. They noted that CGEN-438 expression also appears to be higher in some of those with non-small cell lung cancer.
Based on these results, Compugen said CGEN-438 may ultimately become a useful biomarker for diagnosing small-cell lung cancer and for helping to diagnose non-small cell lung cancer in conjunction with other tests.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.